← All trials
NCT05119751
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Nov 15, 2021
- Last posted
- Nov 15, 2021
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Clinique Spécialisée en Allergies de la CapitaleLead sponsor
- ALK-Abello, S.A.Collaborator
- Clinique Spécialisée en Allergies de la CapitaleOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.